Evaluation of the Risk of Frailty using Blood Metabolite Markers

A novel method to evaluate the risk of frailty in people by analyzing blood.

A novel method to evaluate the risk of frailty in people by analyzing blood.

Abstract

Preventative and Personalized Medicine accounts for about USD 575 billion. According to the Centers for Disease Control (CDC), seven out of 10 U.S. deaths are caused by chronic disease, while roughly half of the country’s population has been diagnosed with a chronic illness, classified by the medical community as preventable. Preventive health is the use of recognized proactive health screenings, counseling and maintenance to prevent future illness and treatment. Globally, human society is aging. A side-effect of this is that age-related disorders such a frailty, are becoming increasingly common. Frailty includes, not only physical disabilities, but also a decline in cognitive function. However, current methods used to diagnose frailty, such as the Edmonton frail scale (EFS), the Montreal cognition assessment (MoCA-J), and the Timed Up and Go Test (TUG), are based on specialized consultation by medical doctors and thus have varying results. Here we present a promising frailty evaluation protocol developed by a group of researchers led by Prof. Mitsuhiro Yanagida. The evaluation protocol is based on the metabolite profile in human blood.

The technology is based on a novel method to more accurately diagnose frailty in the elderly. More specifically, a method is now developed to take a close look at the blood metabolites in elderly patients using a technique called metabolomics. From this method, a profile of 15 metabolites whose levels in the blood correlate with frailty, has been identified. This newly discovered profile can be used to better diagnose a frail person in a consistent manner and provide an opportunity for early intervention and treatment.

Applications

  • Frailty Risk Assessment

Advantages

  • Consistent diagnosis

Website

https://groups.oist.jp/tdic/technology0169